NCT06083883 is a Phase 1 clinical trial of Fludarabine phosphate in Synovial Sarcoma, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT06083883?

NCT06083883 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT06083883?

Interventions in NCT06083883: Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide.

What condition does NCT06083883 study?

NCT06083883 studies Synovial Sarcoma, Myxoid/Round Cell Liposarcoma.

Is NCT06083883 still recruiting?

NCT06083883 is currently recruiting now. Last updated 16 April 2026.

Last reviewed 2026-04-16 · How we verify

NCT06083883

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Recruiting now Phase 1 Last updated 16 April 2026

What this trial tests

Phase 1 trial testing Fludarabine phosphate in Synovial Sarcoma in 44 participants. Currently enrolling.

Timeline

27 March 2024

Primary endpoint
30 November 2026

30 November 2028

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	44
Start date	27 March 2024
Primary completion	30 November 2026
Estimated completion	30 November 2028
Sites	1 location across United States

Drugs / interventions tested

Fludarabine phosphate (FLUDARABINE PHOSPHATE) — full drug profile →
NY-ESO-1 TCR/IL-15 NK — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

Synovial Sarcoma — all drugs for Synovial Sarcoma →
Myxoid/Round Cell Liposarcoma — all drugs for Myxoid/Round Cell Liposarcoma →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 16 to 80, any sex, with Synovial Sarcoma or Myxoid/Round Cell Liposarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.
Chen S, Zhu H, Jounaidi Y. · · 2024 · cited 106× · PMID 39511139 · DOI 10.1038/s41392-024-02005-w
Emerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy.
Verner JM, Arbuthnott HF, Ramachandran R, Bharadwaj M, et al · · 2024 · cited 9× · PMID 38745765 · DOI 10.37349/etat.2024.00219
Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancer.
Rafei H, Rezvani K. · · 2025 · cited 8× · PMID 39622255 · DOI 10.1111/bjh.19939
Review of Adoptive Cellular Therapies for the Treatment of Sarcoma.
Fradin JJ, Charlson JA. · · 2025 · cited 3× · PMID 40282478 · DOI 10.3390/cancers17081302
Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances.
McLaughlin Q, Sojka DK, Kennedy K, Piersma SJ, et al · · 2025 · cited 2× · PMID 40849493 · DOI 10.1186/s13046-025-03503-7
CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy.
Ahrberg Y, Dallmann J, Freitag J, Hassan A, et al · · 2024 · cited 1× · PMID 39043196 · DOI 10.1080/21645515.2024.2381925
Sarcomas in Adolescents and Young Adults.
Greenmyer JR, Allen-Rhoades W. · · 2026 · PMID 42159886 · DOI 10.1007/s11912-026-01781-8
T cell immunotherapy for solid tumors: limitations, progress, and future prospects.
Wang Y, Zhang B, Wang Y, Tan Y, et al · · 2026 · PMID 41694348 · DOI 10.3389/fimmu.2026.1755751

Verify or expand the search:

Other trials of Fludarabine phosphate

Trials testing the same drug.

NCT06345495 — High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly · Phase 2 · recruiting
NCT06434363 — Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Di · Phase 1, PHASE2 · recruiting
NCT06383572 — Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Che · Phase 1, PHASE2 · recruiting
NCT06043323 — A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination · Phase 2 · recruiting
NCT06066359 — Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapse · Phase 1, PHASE2 · recruiting

Other recruiting trials for Synovial Sarcoma

Currently open trials in the same condition.

NCT05642455 — SPEARHEAD-3 Pediatric Study · Phase 1, PHASE2 · recruiting
NCT05492682 — START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer · Phase 1 · active not recruiting
NCT04995003 — HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma · Phase 1 · recruiting
NCT04420975 — Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma · Phase 1 · active not recruiting
NCT04044768 — Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma · Phase 2 · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06083883 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 16 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06083883.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing